Polyrizon Ltd. PLRZ
Regular-session close
After hours · Nov 13, 4:00 PM ET
Day range unavailable
- YTD
- +30.15%
- 1 year
- +139.18%
- Market cap
- 26.84M
- EPS (ttm)
- -4.97
- Shares out
- 4.19M
- YTD return
- +30.15%
- 1-year return
- +139.18%
- Avg volume
- 46.15K
- Previous close
- 11.05
- 52-week range
- 2.88 – 18.20
Key statistics
- Enterprise value
- 5.46M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 23.00K
- Total debt
- 151.00K
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 1.17
- 200-day average
- 1.17
Fundamental scorecard
6 of 25 checks passed on PLRZ’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
About Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- polyrizon-biotech.com
News
Your note
Sign in to keep a note on PLRZ — it syncs with the Stock Master app.
